Regencell Bioscience Holdings (Regencell Bioscience Holdings) Earnings per Share (Diluted) : $-0.45 (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Earnings per Share (Diluted)?

Regencell Bioscience Holdings's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was $-0.20. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

Regencell Bioscience Holdings's EPS (Basic) for the six months ended in Jun. 2023 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

Regencell Bioscience Holdings's EPS without NRI for the six months ended in Jun. 2023 was $-0.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

During the past 3 years, the average EPS without NRIGrowth Rate was -91.60% per year.

During the past 5 years, Regencell Bioscience Holdings's highest 3-Year average EPS without NRI Growth Rate was -91.60% per year. The lowest was -165.50% per year. And the median was -128.55% per year.

Regencell Bioscience Holdings Earnings per Share (Diluted) Historical Data

The historical data trend for Regencell Bioscience Holdings's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Earnings per Share (Diluted) Chart

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Earnings per Share (Diluted)

-0.03

-0.06

-0.11

-0.58

-0.45

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Earnings per Share (Diluted)	Get a 7-Day Free Trial				-0.08	-0.29	-0.29	-0.25	-0.20

Competitive Comparison of Regencell Bioscience Holdings's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's PE Ratio falls into.

Regencell Bioscience Holdings Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Regencell Bioscience Holdings's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-5.871	-	0)	/	13.013
	=	-0.45

Regencell Bioscience Holdings's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-2.644	-	0)	/	13.013
	=	-0.20

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.45

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Regencell Bioscience Holdings (NAS:RGC) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Regencell Bioscience Holdings Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.